Henry I. Miller and Jeff Stier

Avastin Shouldn’t Make the FDA Give Up on ‘Accelerated Approval’ of Drugs

An important but obscure aspect of the Food and Drug Administration’s regulation of drugs has been in the news in recent months. Called “accelerated approval,” this “quick-on, quick-off” mechanism for medicines to reach the marketplace can work to the advantage of drug companies and needy patients alike. Introduced almost two decades ago, accelerated approval permits ... Read more »